IPP Bureau
AstraZeneca opens Discovery Centre in Cambridge
By IPP Bureau - November 23, 2021
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
Obseva announces U.S. FDA acceptance of new drug application for linzagolix
By IPP Bureau - November 23, 2021
Obseva announced previously that the company has entered into a partnership with Syneos Health to support commercialization of linzagolix in the US and EU
Boehringer Ingelheim gets CDSCO nod for Jardiance
By IPP Bureau - November 23, 2021
Jardiance is the first SGLT2-inhibitor therapy to prove reduction in risk of cardiovascular death in people with type-II diabetes and established cardiovascular disease
U.S. FDA approves Alembic’s Formoterol Fumarate inhalation solution
By IPP Bureau - November 23, 2021
The ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
Zydus Cadila submits NDA to Drug Controller General of India for Chronic Kidney Disease
By IPP Bureau - November 23, 2021
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
Alembic receives tentative U.S. FDA approval for Dabigatran Etexilate capsules
By IPP Bureau - November 23, 2021
Dabigatran Etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE)
Cognota Healthcare partners with Dr Jahangir Alam in his digital foray
By IPP Bureau - November 23, 2021
The platform is a collaborative video solution that enables doctors and medical staff to deliver seamless health care experiences to patients through this digital interface
Philips integrates MedChat’s AI to optimise automated patient communication
By IPP Bureau - November 23, 2021
Hospitals and outpatient clinics can also digitally navigate patients from the time an order is placed, to when it is scheduled and completed through follow-up
CStone and Jiangsu Hengrui sign exclusive licensing agreement for cancer drugs in China
By IPP Bureau - November 22, 2021
CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
European Commission approves Roche’s Gavreto
By IPP Bureau - November 22, 2021
Gavreto is the first and only precision medicine approved in the EU for first-line treatment of people with RET fusion-positive advanced NSCLC
Amneal gets approval for Difluprednate ophthalmic emulsion
By IPP Bureau - November 22, 2021
The company is moving towards complex and more differentiated products
FDA grants Theradaptive Breakthrough Medical Device designation
By IPP Bureau - November 22, 2021
Theradaptive's regenerative implants are best-in-class and are designed to permit precise tissue regeneration for a variety of tissue types and clinical indications
HCG acquires Suchirayu Healthcare Solutions
By IPP Bureau - November 22, 2021
Suchirayu owns a state-of-the-art multi-speciality hospital in Hubli with an operational capacity of 110 beds and a potential to scale up to 250 beds
Merck showcases potential for several cancers, MS and lupus
By IPP Bureau - November 22, 2021
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Funding push to pharma R&D critical for unleashing next phase of growth
By IPP Bureau - November 20, 2021
The industry is at an inflection point and it awaits mega investments, the right government policies, and the creation of a strong ecosystem to propel innovation
